Medicure Inc. logo

Medicure Inc. (NGQ1)

Market Closed
10 Aug, 19:03
XSTU XSTU
0. 74
+0
+0.6849%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
0.73
Previous Close
Add Transaction
Day Range
0.73 0.82
Year Range
0.49 0.85
Want to track NGQ1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NGQ1 closed yesterday higher at €0.74, an increase of 0.6849% from Friday's close, completing a monthly decrease of -6.3694% or -€0.05. Over the past 12 months, NGQ1 stock gained 6.5217%.
NGQ1 is not paying dividends to its shareholders.
The last earnings report, released on Apr 24, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Medicure Inc. has completed 1 stock splits, with the recent split occurring on Nov 02, 2012.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

NGQ1 Chart

Medicure Inc. (NGQ1) FAQ

What is the stock price today?

The current price is €0.74.

On which exchange is it traded?

Medicure Inc. is listed on XSTU.

What is its stock symbol?

The ticker symbol is NGQ1.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Medicure Inc. ever had a stock split?

Medicure Inc. had 1 splits and the recent split was on Nov 02, 2012.

Medicure Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Albert David Friesen CEO
XSTU Exchange
CA58469E4085 ISIN
CA Country
23 Employees
- Last Dividend
2 Nov 2012 Last Split
29 Mar 1999 IPO Date

Overview

Medicure Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic solutions for the cardiovascular market. Since its incorporation in 1997, Medicure has aimed to address the urgent needs of patients suffering from cardiovascular diseases with innovative and effective treatments. With its headquarters in Winnipeg, Canada, the company has established a significant presence in the pharmaceutical industry, focusing on improving patient outcomes through its specialized products and services. Medicure’s commitment to research and development in the cardiovascular domain reflects its dedication to advancing healthcare and making a positive impact on patients' lives worldwide.

Products and Services

Medicure Inc. offers a carefully curated range of products focused on addressing various cardiovascular conditions, with each product tailored to meet the specific needs of patients:

  • AGGRASTAT Injection

    As a glycoprotein GP IIb/IIIa receptor antagonist, AGGRASTAT is designed for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. This formulation plays a crucial role in preventing platelet aggregation, a key factor in the development of coronary artery blockages, thereby aiding in the management of critical heart conditions.

  • ZYPITAMAG

    Targeting individuals with primary hyperlipidemia or mixed dyslipidemia, ZYPITAMAG is a therapeutic solution aimed at treating patients struggling with challenging cholesterol levels. By managing lipid profiles effectively, ZYPITAMAG helps reduce the risk of cardiovascular diseases, promoting healthier heart functions and preventing further complications.

  • Sodium Nitroprusside Injection

    This product is crucial for the rapid reduction of blood pressure in adult and pediatric patients experiencing hypertensive crises. It’s also utilized for producing controlled hypotension during surgery to minimize blood loss and for treating acute congestive heart failure. Sodium Nitroprusside’s versatile application in critical care settings underscores Medicure’s commitment to supporting life-saving interventions.

Medicure ensures these products are accessible through both retail and mail-order pharmacies, facilitating ease of access for patients requiring timely and effective cardiovascular therapies.

Contact Information

Address: 2-1250 Waverley Street
Phone: 204 487 7412